
Stanley Friedman
Examiner (ID: 12067)
| Most Active Art Unit | 1205 |
| Art Unit(s) | 1802, 1803, 2607, 1205 |
| Total Applications | 1808 |
| Issued Applications | 1509 |
| Pending Applications | 0 |
| Abandoned Applications | 299 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 19613243
[patent_doc_number] => 20240398923
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-12-05
[patent_title] => SUBUNIT VACCINE DELIVERY PLATFORM FOR ROBUST HUMORAL AND CELLULAR IMMUNE RESPONSES
[patent_app_type] => utility
[patent_app_number] => 18/661174
[patent_app_country] => US
[patent_app_date] => 2024-05-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17996
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18661174
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/661174 | SUBUNIT VACCINE DELIVERY PLATFORM FOR ROBUST HUMORAL AND CELLULAR IMMUNE RESPONSES | May 9, 2024 | Abandoned |
Array
(
[id] => 19599509
[patent_doc_number] => 20240390389
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-28
[patent_title] => HETEROCYCLIC COMPOUNDS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/634495
[patent_app_country] => US
[patent_app_date] => 2024-04-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 150807
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18634495
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/634495 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Apr 11, 2024 | Pending |
Array
(
[id] => 19402054
[patent_doc_number] => 20240285565
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-29
[patent_title] => USE OF (S)-3-AMINO-4-(DIFLUOROMETHYLENYL)CYCLOPENT-1-ENE-1-CARBOXYLIC ACID IN THE TREATMENT OF DIABETES AND PRE-DIABETES
[patent_app_type] => utility
[patent_app_number] => 18/443583
[patent_app_country] => US
[patent_app_date] => 2024-02-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9671
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18443583
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/443583 | USE OF (S)-3-AMINO-4-(DIFLUOROMETHYLENYL)CYCLOPENT-1-ENE-1-CARBOXYLIC ACID IN THE TREATMENT OF DIABETES AND PRE-DIABETES | Feb 15, 2024 | Pending |
Array
(
[id] => 19065615
[patent_doc_number] => 20240100041
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-28
[patent_title] => COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE USING CCR9 INHIBITOR AND ANTI-IL-23 BLOCKING ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 18/531086
[patent_app_country] => US
[patent_app_date] => 2023-12-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15156
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18531086
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/531086 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE USING CCR9 INHIBITOR AND ANTI-IL-23 BLOCKING ANTIBODIES | Dec 5, 2023 | Pending |
Array
(
[id] => 18844441
[patent_doc_number] => 20230406845
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-12-21
[patent_title] => NOVEL POTASSIUM CHANNEL INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 18/239348
[patent_app_country] => US
[patent_app_date] => 2023-08-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 39399
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 270
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18239348
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/239348 | Potassium channel inhibitors | Aug 28, 2023 | Issued |
Array
(
[id] => 18808668
[patent_doc_number] => 20230383002
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-30
[patent_title] => HUMANIZED BCMA ANTIBODY AND BCMA-CAR-T CELLS
[patent_app_type] => utility
[patent_app_number] => 18/326826
[patent_app_country] => US
[patent_app_date] => 2023-05-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5192
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 28
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18326826
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/326826 | Humanized BCMA antibody and BCMA-CAR-T cells | May 30, 2023 | Issued |
Array
(
[id] => 18763998
[patent_doc_number] => 11814384
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-11-14
[patent_title] => Inhibtors of Raf kinases
[patent_app_type] => utility
[patent_app_number] => 18/164326
[patent_app_country] => US
[patent_app_date] => 2023-02-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 79879
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 101
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18164326
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/164326 | Inhibtors of Raf kinases | Feb 2, 2023 | Issued |
Array
(
[id] => 18709115
[patent_doc_number] => 20230331718
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-19
[patent_title] => COMPOSITIONS FOR MODULATING SPLICING
[patent_app_type] => utility
[patent_app_number] => 18/162085
[patent_app_country] => US
[patent_app_date] => 2023-01-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30594
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18162085
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/162085 | COMPOSITIONS FOR MODULATING SPLICING | Jan 30, 2023 | Pending |
Array
(
[id] => 19059022
[patent_doc_number] => 11938217
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-03-26
[patent_title] => Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate
[patent_app_type] => utility
[patent_app_number] => 18/098505
[patent_app_country] => US
[patent_app_date] => 2023-01-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5986
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 90
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18098505
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/098505 | Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate | Jan 17, 2023 | Issued |
Array
(
[id] => 19768397
[patent_doc_number] => 20250049823
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-02-13
[patent_title] => MITOCHONDRIAL ATP INHIBITORS TARGETING THE GAMMA SUBUNIT PREVENT METASTASIS
[patent_app_type] => utility
[patent_app_number] => 18/722474
[patent_app_country] => US
[patent_app_date] => 2022-12-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13209
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 28
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18722474
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/722474 | MITOCHONDRIAL ATP INHIBITORS TARGETING THE GAMMA SUBUNIT PREVENT METASTASIS | Dec 21, 2022 | Pending |
Array
(
[id] => 19768339
[patent_doc_number] => 20250049765
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-02-13
[patent_title] => BICYCLO [3.2.0] HEPTANE BIS(AMIDE) RXFP1 AGONISTS
[patent_app_type] => utility
[patent_app_number] => 18/718484
[patent_app_country] => US
[patent_app_date] => 2022-12-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15999
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 447
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18718484
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/718484 | BICYCLO [3.2.0] HEPTANE BIS(AMIDE) RXFP1 AGONISTS | Dec 13, 2022 | Pending |
Array
(
[id] => 18374280
[patent_doc_number] => 20230149358
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-18
[patent_title] => COMBINATION CANCER THERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX AND HORMONE THERAPY AGENT
[patent_app_type] => utility
[patent_app_number] => 18/071724
[patent_app_country] => US
[patent_app_date] => 2022-11-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 47536
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18071724
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/071724 | COMBINATION CANCER THERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX AND HORMONE THERAPY AGENT | Nov 29, 2022 | Pending |
Array
(
[id] => 19754297
[patent_doc_number] => 20250042862
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-02-06
[patent_title] => AROMATIC HETEROCYCLIC COMPOUND AND APPLICATION THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/709473
[patent_app_country] => US
[patent_app_date] => 2022-11-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22201
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18709473
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/709473 | AROMATIC HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | Nov 9, 2022 | Pending |
Array
(
[id] => 18793890
[patent_doc_number] => 11827642
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-11-28
[patent_title] => Compositions useful for treating disorders related to KIT
[patent_app_type] => utility
[patent_app_number] => 17/983747
[patent_app_country] => US
[patent_app_date] => 2022-11-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 24860
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 37
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17983747
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/983747 | Compositions useful for treating disorders related to KIT | Nov 8, 2022 | Issued |
Array
(
[id] => 18916698
[patent_doc_number] => 11878968
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-01-23
[patent_title] => Aryl compounds and pharmaceutical compositions that modulate IKZF2
[patent_app_type] => utility
[patent_app_number] => 18/052462
[patent_app_country] => US
[patent_app_date] => 2022-11-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30843
[patent_no_of_claims] => 40
[patent_no_of_ind_claims] => 18
[patent_words_short_claim] => 5
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18052462
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/052462 | Aryl compounds and pharmaceutical compositions that modulate IKZF2 | Nov 2, 2022 | Issued |
Array
(
[id] => 18437482
[patent_doc_number] => 20230184777
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-15
[patent_title] => DIAGNOSIS AND TREATMENT OF CANCER
[patent_app_type] => utility
[patent_app_number] => 18/046606
[patent_app_country] => US
[patent_app_date] => 2022-10-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16732
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18046606
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/046606 | DIAGNOSIS AND TREATMENT OF CANCER | Oct 13, 2022 | Pending |
Array
(
[id] => 18384471
[patent_doc_number] => 11655240
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2023-05-23
[patent_title] => Crystal form of compound and fumaric acid, pharmaceutical composition and method for treating coronavirus-induced diseases
[patent_app_type] => utility
[patent_app_number] => 17/964389
[patent_app_country] => US
[patent_app_date] => 2022-10-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 7
[patent_no_of_words] => 18555
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 48
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17964389
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/964389 | Crystal form of compound and fumaric acid, pharmaceutical composition and method for treating coronavirus-induced diseases | Oct 11, 2022 | Issued |
Array
(
[id] => 19691203
[patent_doc_number] => 20250009748
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-01-09
[patent_title] => COMBINATION THERAPY USING SUBSTITUTED PYRIMIDIN-4(3H)-ONES AND SOTORASIB
[patent_app_type] => utility
[patent_app_number] => 18/696931
[patent_app_country] => US
[patent_app_date] => 2022-09-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 38622
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -59
[patent_words_short_claim] => 51
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18696931
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/696931 | COMBINATION THERAPY USING SUBSTITUTED PYRIMIDIN-4(3H)-ONES AND SOTORASIB | Sep 29, 2022 | Pending |
Array
(
[id] => 18701291
[patent_doc_number] => 11787790
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-10-17
[patent_title] => Benzimidazole derivative having fluorine-containing substituent, preparation and application thereof
[patent_app_type] => utility
[patent_app_number] => 17/947260
[patent_app_country] => US
[patent_app_date] => 2022-09-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4218
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 241
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17947260
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/947260 | Benzimidazole derivative having fluorine-containing substituent, preparation and application thereof | Sep 18, 2022 | Issued |
Array
(
[id] => 18724411
[patent_doc_number] => 20230338569
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-26
[patent_title] => NaPi2b-TARGETED POLYMER ANTIBODY-DRUG CONJUGATE FOR THE TREATMENT OF OVARIAN CANCER
[patent_app_type] => utility
[patent_app_number] => 17/930924
[patent_app_country] => US
[patent_app_date] => 2022-09-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19079
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 277
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17930924
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/930924 | NaPi2b-TARGETED POLYMER ANTIBODY-DRUG CONJUGATE FOR THE TREATMENT OF OVARIAN CANCER | Sep 8, 2022 | Abandoned |